Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Bayer's Monsanto Scores Legal Victory as $185M Verdict Overturned

Published 02/05/2024, 18:38
Updated 02/05/2024, 19:40
© Reuters.  Bayer's Monsanto Scores Legal Victory as $185M Verdict Overturned
BAYRY
-

Benzinga - by Vandana Singh, Benzinga Editor.

Bayer AG’s (OTC:BAYRY) (OTC:BAYZF) Monsanto unit secured a significant victory. A Washington state appeals court overturned a $185 million verdict against the company over chemical contamination at a Seattle-area school.

This marks the second major legal win for the company in recent weeks. The original lawsuit, brought by three teachers who claimed they suffered brain damage from exposure to now-banned chemicals called polychlorinated biphenyls (PCBs), dates back to 2021 when Monsanto spinoff Pharmacia was found liable.

The state Court of Appeals ruled that the lower court improperly applied Missouri laws, where Monsanto is based, Reuters highlights, allowing the claims to be filed decades after the company ceased PCB production in 1977.

Also Read: German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer-Related Lawsuits.

This decision highlights a broader legal battle over PCBs and the alleged cancer-causing effects of glyphosate, the active ingredient in Monsanto’s Roundup weed killer.

The U.S. government banned PCBs in 1979 after discovering their link to cancer, yet litigation over their effects has persisted, impacting Bayer’s shares significantly.

Bayer argued that Washington law limits liability for exposure outside a product’s useful lifespan, typically 12 years.

Despite the victory, the case will return to the lower court to determine if a new trial is necessary.

Bayer faces approximately 200 similar claims from the school, alleging various health issues due to PCB exposure.

The company views the appeals court’s identification of multiple errors as highly significant and is considering its legal options regarding this ruling and its potential implications on future trials.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The ruling is part of a series of legal battles inherited by Bayer following its acquisition of Monsanto in 2018, including lawsuits alleging Roundup’s cancer-causing properties.

Financially, Bayer’s exposure in PCB contamination claims could surpass $2.5 billion, with over $650 million already paid in settlements over waterway pollution lawsuits, according to Bloomberg Intelligence.

Read Next: Google Partners With European Conglomerate Bayer For New AI-Powered Solutions For Radiologists.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo via Wikimedia Commons

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.